INTRODUCTION {#s1}
============

CRC represents the third most common cause of cancer-related death in men and women in the united states \[[@R1]\]. It is estimated that 134,490 new cases will be diagnosed and 49,190 deaths will occur in 2016 \[[@R1]\]. Despite advances in surveillance, diagnosis and treatment of CRC, a large number of the patients are still diagnosed at an advanced stage and thus the therapeutic options are limited, resulting in a 5-year survival rate of only about 65% much lower than expected \[[@R2]\]. The discovery of prognostic factors is of clinical importance to guide therapeutic options and surveillance strategies. However, the prognoses of CRC patients with similar clinicopathologic characteristics vary widely due to high heterogeneity in tumor biology \[[@R3]\]. Currently, the discovery of prognostic biomarkers mainly depends on surgical specimens, which may not be representative of the veritable burden of CRC \[[@R4]\]. In addition, as many prognostic factors are evaluated postoperatively, there are still pending circulating biomarkers of early predicting clinical outcome.

Recently, there has been intense interest in the prognostic value of peripheral blood biomarkers in CRC. Inflammation has been reported to be involved in carcinogenesis and disease progression \[[@R5]\] and local cancer-related inflammation can be reflected by a systemic inflammatory response (SIR). Nearly a third of cancer patients have thrombocytosis at diagnosis and aberrant activation of platelets has been shown to be associated with CRC \[[@R6], [@R7]\]. Lymphocytes are essential components of the tumor microenvironment, which contributes to carcinogenesis \[[@R8]\]. Monocytes have been reported to influence CRC progression and can be used to predict prognosis \[[@R9], [@R10]\]. PLR and LMR, two representative indices of SIR, have been found to impact survival in a variety of solid malignancies \[[@R11]--[@R14]\], including CRC \[[@R15], [@R16]\]. As the collection of circulating inflammatory markers, including PLR and LMR, is simple, noninvasive, and easily accessible. Circulating levels of inflammatory markers have been investigated as applicable and cost-effective prognostic predictors in cancer patients \[[@R17]\]. Although the underlying mechanisms of altered PLR and LMR in CRC development remains unknown, numerous studies have investigated their value as prognostic factors and markers for predicting response to therapy. However, the results of these studies are conflicting \[[@R16], [@R18], [@R19]\]. Therefore, a comprehensive evaluation of the literature is warranted.

In the present study, this meta-analysis represents the most comprehensive and up-to-date review on the prognostic value of PLR and LMR in CRC. The results of this study showed that elevated PLR and LMR were associated with poor and favorable prognosis in CRC, respectively, suggesting that these two factors might be used as prognostic factors in CRC patients and applied in surveillance programs.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

Cohen\'s kappa for inter-reviewer agreement was 0.80 (95% CI=0.69 to 0.93). The literature search process is summarized in a PRISMA flow diagram (Figure [1](#F1){ref-type="fig"}). Initial assessment of titles and abstracts identified 346 potentially relevant publications which included 170 duplicates, 94 irrelevant studies, and 28 non-research articles. After further screening of full-texts of the remaining 54 articles, 21 papers were excluded due to insufficient survival data or for being a secondary publication. Altogether, 33 studies \[[@R3], [@R16], [@R18]--[@R48]\] were finally selected for inclusion. Among these studies, 22 investigated PLR, 8 studied LMR and 3 evaluated both PLR and LMR.

![Flow- diagram shows the selection of literature for meta-analysis](oncotarget-08-20011-g001){#F1}

Study description {#s2_2}
-----------------

The basic features of the 33 studies are summarized in Table [1](#T1){ref-type="table"}. In total, 15,404 patients were included. All included studies were retrospective cohorts. Among these studies, 2 were published in 2012, 4 in 2013, and the remaining 27 (82%) were published in 2014 or later. Sample sizes ranged from 57 to 5336 patients. The mean or median age of subjects ranged from 49 to 71.3 years. The mean or median follow-up duration ranged from 10.4 to 68 months. Patients in 23 studies \[[@R3], [@R16], [@R23], [@R24], [@R26], [@R27], [@R29]--[@R37], [@R40]--[@R44], [@R46]--[@R48]\] were Asian, while subjects were Caucasian in the other 10 studies \[[@R18]--[@R22], [@R25], [@R28], [@R38], [@R39], [@R45]\]. 6 studies \[[@R16], [@R41]--[@R44]\] included all CRC stages; 16 studies \[[@R3], [@R18], [@R20], [@R21], [@R23], [@R24], [@R27], [@R28], [@R30], [@R31], [@R33], [@R34], [@R37], [@R40], [@R45], [@R48]\] only included non-metastatic CRC; 10 studies \[[@R19], [@R22], [@R26], [@R29], [@R35], [@R36], [@R38], [@R39], [@R45]--[@R47]\] only included metastatic CRC; and 1 study \[[@R45]\] included two cohorts evaluating the outcomes of both non-metastatic and metastatic CRC. Twenty three studies analyzed PLR as a single dichotomous cut-off (group 1), while three studies \[[@R3], [@R38], [@R48]\] defining three risk categories with two cut-offs reported a single HR of PLR (group 2). All studies evaluated LMR as a dichotomous cut-off.

###### Baseline characteristics of studies included in this meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study\                     Country\       Sample size\         Main treatment\      Study design\    Outcome indices\    Follow-up\           Cut-off\                       determine the\     inflammatory disorders   Study quality\#
  Published year             Duration       Median age           Tumor site           Clinical stage   Survival analysis   (median and range)   value                          cut-off value                               
  -------------------------- -------------- -------------------- -------------------- ---------------- ------------------- -------------------- ------------------------------ ------------------ ------------------------ -----------------
  Baranyai *et al*. 2013     USA\           336\                 CSR\                 Retrospective\   OS,DFS\             67                   PLR:300                        RPS                No                       6
                             2001-2011      CRC:67               CRC                  N                MVA                                                                                                                 

  Baranyai *et al*. 1 2013   USA\           118\                 mCRC                 Retrospective\   OS\                 NR                   PLR:300                        RPS                No                       6
                             2001-2011      mCRC:61\*                                 M                MVA                                                                                                                 

  Carruthers *et al*.\       UK\            115\                 NeoCRT/adjCT +CSR\   Retrospective\   OS,DFS\             37.1                 PLR:160                        RPS                NR                       6
  2012                       2000-2005      63.8(32.3--81.1)\*   RC                   N                UVA                                                                                                                 

  Chan et al.\               Australia\     1623\                CRT +CSR\            Retrospective\   OS\                 52(27-92)            PLR:258\                       MaxStat analysis   NR                       7
  2016                       1998-2012      NR                   CRC                  N                PLR:UVA;LMR:MUV                          LMR:2.38                                                                   

  Choi et al.\               Canada\        549\                 CSR\                 Retrospective\   OS,RFS/DFS\         48(0-124.8)          PLR:295                        MaxStat analysis   NR                       8
  2015                       2004-2012      68.7(68.3-98.6)      CRC                  N                UVA                                                                                                                 

  Chen et al.\               China\         205\                 CSR\                 Retrospective\   RFS/DFS\            NR                   PLR:176                        ROC analysis       NR                       6
  2015                       2010-2014      NR                   CRC                  N                MVA                                                                                                                 

  Cui et al.\                China\         822\                 CSR±adjCT/CRT\       Retrospective\   OS,RFS/DFS\         NR                   PLR:194                        ROC analysis       NO                       7
  2015                       2007-2011      NR                   CRC                  N                MVA                                                                                                                 

  Duan et al.\               China\         57\                  CSR\                 Retrospective\   OS\                 NR                   PLR:250                        NR                 NR                       5
  2014                       2007-2008      71.3\*               CRC                  NM               MVA                                                                                                                 

  Kwon et al.\               South Korea\   200\                 CSR±adjCT/CRT\       Retrospective\   OS\                 33.6                 PLR:\<150 / 150-300 / \>300    NR                 NR                       8
  2012                       2005-2008      64(26--83)           CRC                  N                MVA                                                                                                                 

  Li et al.\                 China\         5,336\               CSR±adjCT\           Retrospective\   OS,DFS\             55.2                 PLR:219\                       X-tile software    NO                       9
  2016                       2007-2014      59(51--66)           CRC                  N                MVA                                      LMR:2.83                                                                   

  Li et al.\                 China\         110\                 PSR+CT\              Retrospective\   OS\                 10.4(0.9-122.2)      PLR:162                        NR                 NR                       7
  2015                       2003-2012      62.9\*               CC                   M                MVA                                                                                                                 

  Lin et al.\                China\         488\                 CT\                  Retrospective\   OS\                 23.5(4.3--32.8)      LMR:3.11                       ROC                NO                       9
  2016                       2005-2013      54(37-72)            CRC                  M                MVA                                                                                                                 

  Liu et al.\                China\         140\                 CSR\                 Retrospective\   OS\                 NR                   PLR:250                        NR                 NR                       6
  2013                       2005-2011      54.1\*               CRC                  NM               MVA                                                                                                                 

  Luo et al.\                China\         162\                 NR\                  Retrospective\   OS\                 NR                   PLR:250                        NR                 NR                       5
  2014                       2006-2010      NR                   CRC                  NM               MVA                                                                                                                 

  Mori et al.\               Japan\         157\                 CSR\                 Retrospective\   DFS\                20.5(0.2--62.4)      PLR:150                        RPS                NO                       7
  2015                       2007-2011      67(35-89)            CRC                  N                UVA                                                                                                                 

  Neal et al.\               UK\            302\                 CSR±CT\              Retrospective\   OS,CSS\             29.7(4-96)           PLR:\<150 / 150-300 / \>300\   PLR:RPC\           NO                       8
  2015                       2006-2010      64.8\*(26-85)        CRLM                 M                UVA                                      LMR:2.35                       LMR:ROC                                     

  Neofytou *et al*.\         UK\            140\                 NeoCT/adjCT +CSR\    Retrospective\   OS,DFS\             33(1-103)            PLR:150                        ROC analysis       NO                       9
  2014                       2005-2012      NR                   CRLM                 M                MVA                                                                                                                 

  Neofytou *et al*.\         UK\            140\                 NeoCT/adjCT +CSR\    Retrospective\   OS,CSS MVA\         33(1-103)            LMR:3                          ROC analysis       NO                       9
  2015                       2005-2012      NR                   CRLM                 M                DFS UVA                                                                                                             

  Ni et al.\                 China\         148\                 CT\                  Retrospective\   OS\                 12(0.2-67)           PLR:174                        RPS                NO                       8
  2016                       2010-2015      60.2\*(20-74)        CRC                  M                MVA                                                                                                                 

  Ozawa *et al*.\            Japan\         234\                 CSR\                 Retrospective\   DFS,CSS\            64(1-173)            PLR:25.4                       ROC analysis       NO                       9
  2015                       2000-2010      NR                   CRC                  N                MVA                                                                                                                 

  Ozawa *et al*. 1\          Japan\         117\                 CSR\                 Retrospective\   DFS,CSS\            39(4-170)            LMR:3                          ROC analysis       NO                       9
  2015                       1997-2012      NR                   CRC                  M                MVA                                                                                                                 

  Passardi *et al*.\         Italy\         289\                 CT\                  Prospective\     OS,PFS\             NR                   PLR:169                        X-tile software    NR                       8
  2016                       NR             NR                   CRC                  M                MVA                                                                                                                 

  Shibutani *et al*.\        Japan\         104\                 CT\                  Retrospective\   OS\                 22.4(2.6-69.5)       LMR:3.38                       ROC analysis       NR                       6
  2015                       2005-2010      64(27-86)            CRC                  M                MVA                                                                                                                 

  Son et al.\                South Korea\   624\                 CSR\                 Retrospective\   OS,DFS\             42(1-66)             PLR:300                        NR                 NR                       7
  2013                       2005-2007      NR                   CRC                  N                MVA                                                                                                                 

  Song et al.\               South Korea\   177\                 RVS\                 Retrospective\   OS\                 3.1(0.1-33.3)        LMR:3.4                        ROC analysis       NR                       7
  2015                       2006-2003      52(25-81)            CRC                  M                UVA                                                                                                                 

  Stotz *et al*.\            Austria\       372\                 CSR\                 Retrospective\   OS\                 68(1-190)            LMR:2.14                       ROC analysis       NR                       8
  2014                       1996-2011      64(27-95)            CR                   N                MVA                                                                                                                 

  Sun et al.\                China\         255\                 CSR\                 Retrospective\   OS,DFS\             NR                   PLR:\<150 / 150-300 / \>300    NR                 NR                       7
  2014                       2005-2008      59.47\*              CC                   N                MVA                                                                                                                 

  Szkandera *et al*.\        Austria\       372\                 CSR\                 Retrospective\   OS\                 68(1-190)            PLR:225                        ROC analysis       NR                       8
  2014                       1996-2011      64(27-95)            CC                   N                MVA                                                                                                                 

  Toiyama *et al*.\          Japan\         84\                  CRT+CSR\             Retrospective\   OS,DFS\             56(2-147)            PLR:150                        RPS                NR                       7
  2013                       2001-2012      64.5(33-80)          RC                   N                UVA                                                                                                                 

  Xiao et al.\               China\         280\                 CSR\                 Retrospective\   DFS\                52(0.5-106.37)       LMR:3.78                       median value       NR                       7
  2015                       2004-2011      NR                   RC                   N                MVA                                                                                                                 

  Ying et al.\               China\         205\                 CSR\                 Retrospective\   RFS,OS,CSS\         NR                   PLR:176                        ROC analysis       NO                       7
  2014                       2005-2010      NR                   CRC                  N                MVA                                                                                                                 

  You et al.\                China\         1314\                CSR\                 Retrospective\   DFS,OS\             56.9                 PLR:150                        RPS                No                       8
  2016                       2005-2011      66\*                 CRC                  NM               MVA                                                                                                                 

  Yu et al.\                 China\         125\                 CT\                  Retrospective\   PFS,OS\             NR                   LMR:3.6                        ROC analysis       NO                       6
  2016                       2011-2014      49(18-72)            CRC                  M                MVA                                                                                                                 

  Zou et al.\                China\         216\                 CSR\                 Retrospective\   OS\                 38(3′85 )            PLR: 246.36                    ROC analysis       No                       8
  2016                       2006-2012      NR                   CRC                  NM               MVA                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Notes: Tumor site : CRC colorectal cancer, mCRC metastatic colorectal cancer, CC colon cancer, RC rectal cancer, CRLM colorectal liver metastases. Treatment: CSR curative surgical resection, PSR palliative surgical resection, CRT chemoradiotherapy, CT chemotherapy, neoCRT neoadjuvant chemoradiotherapy, adjCT adjuvant chemotherapy, RVS Rhus verniciflua stokes. Study design: prospective, retrospective Clinical stage: N nonmetastatic, M metastatic, NM nonmetastatic and metastatic.Outcome indices: OS overall survival, DFS disease-free survival, CSS cancer specific survival, PFS progression-free survival, RFS recurrence-free survival.Survival analysis: MVA multivariate analysis, UVA univariate analysis. Determine the cut-off value: RPS refer to the previous study, NR not reported, ROC receiver operating curve analysis, X-tile 3.6.1 software R package MaxStat \#Study quality was determined based on the Newcastle-Ottawa Scale (range, 1--9) \*Mean

Impact of PLR on OS and DFS in CRC Patients {#s2_3}
-------------------------------------------

Twenty studies \[[@R16], [@R18]--[@R21], [@R23], [@R24], [@R28], [@R29], [@R31], [@R32], [@R37], [@R39]--[@R45]\] in group1, which included 12,760 CRC patients, reported an association between PLR and OS. As seen in Figure [2](#F2){ref-type="fig"}, the analysis of pooled data showed that elevated PLR was correlated with poor OS in group1 (pooled HR = 1.57, 95% CI: 1.41-1.75, *p*\< 0.00001, I^2^=26%, Figure [2A](#F2){ref-type="fig"}). Furthermore, the results of subgroup indicated that increased PLR was a marker for poor prognosis in non-metastatic CRC (pooled HR = 1.59, 95% CI: 1.32 -- 1.91, *p*\< 0.00001, Figure [2A](#F2){ref-type="fig"}), metastatic CRC (pooled HR = 1.57, 95% CI: 1.20 -- 2.04, *p*\< 0.00001, Figure [2A](#F2){ref-type="fig"}) and patients at all stages (pooled HR = 1.55, 95% CI: 1.32 -- 1.81, *p*\< 0.00001, Figure [2A](#F2){ref-type="fig"}). For studies in group 2 (two cut-offs, usually \<150, 150--300, \>300), the pooled HR for OS per risk category was 1.21 (95% CI, 0.82--1.78, *p* = 0.10, Figure [2B](#F2){ref-type="fig"}). Fourteen studies \[[@R16], [@R19], [@R21], [@R23], [@R24], [@R27], [@R28], [@R30], [@R31], [@R33], [@R37], [@R39], [@R40], [@R45]\] comprising 10,410 CRC patients investigated the association between PLR and DFS. As shown in Figure [3](#F3){ref-type="fig"}, patients with high pretreatment PLR had significantly shorter DFS (pooled HR = 1.58, 95% CI: 1.31 -- 1.92, *p*\< 0.00001, I^2^=66%), suggesting that elevated PLR was associated with poor DFS.

![Forest plot reflects the association between PLR and OS\
**A**. group 1, a single cutoff for PLR. **B**. group 2, two cutoffs for PLR.](oncotarget-08-20011-g002){#F2}

![Forest plot reflects the association between PLR and DFS](oncotarget-08-20011-g003){#F3}

Impact of LMR on OS,CSS and DFS in CRC Patients {#s2_4}
-----------------------------------------------

Nine studies \[[@R18], [@R20], [@R25], [@R26], [@R31], [@R35], [@R38], [@R39], [@R47]\] which included a total of 8667 CRC patients provided data for OS. As depicted in Figure [4](#F4){ref-type="fig"}, pooled data showed that elevated LMR was correlated with favorable OS in CRC patients(pooled HR = 0.59, 95% CI: 0.50 -- 0.68, *p*\< 0.00001, I^2^=44%, Figure [4A](#F4){ref-type="fig"}). Subgroup statistics indicated that this prognostic role of LMR was observed in both metastatic or non-metastatic CRC patients (pooled HR = 0.60, 95% CI = 0.51 -- 0.70, *p*\< 0.001 and pooled HR =0.58, 95% CI = 0.41 -- 0.82, *p=*0.002, respectively, Figure [4A](#F4){ref-type="fig"}). The pooled statistics of three studies \[[@R36], [@R38], [@R39]\], which studied the correlation between LMR and CSS, suggested that elevated LMR was a prognostic factor for favorable CSS (pooled HR = 0.54, 95% CI: 0.40 -- 0.72, *p*\< 0.00001, I^2^=11%, Figure [4B](#F4){ref-type="fig"}). Our results also revealed that LMR was a predictor for prolonged DFS (pooled HR = 0.82, 95% CI: 0.71 -- 0.94, *p*=0.005, I^2^=29%, Figure [4C](#F4){ref-type="fig"}).

![Forest plot reflects the association between LMR and OS\
**A**. CSS **B**. DFS **C**.](oncotarget-08-20011-g004){#F4}

Subgroup analysis {#s2_5}
-----------------

Exploratory subgroup analyses were conducted according to geographic region (Asia and non-Asia), sample size (large and small), disease stage (metastatic/mixed and non-metastatic disease), methods for survival analysis(multivariable and univariate analysis), cut-off (≥185 and \<185) and methods for determining cut-off (ROC/software analysis and referring to the previous study). However, results of the subgroup analysis for these variables did not alter the prognostic roles of PLR on OS and DFS and LMR on OS. While LMR was not associated with DFS in the non-Asian, small sample size, metastatic/mixed, univariate analysis and cut-off value≥3.0 subgroups. The difference is more likely clinically insignificant in these subgroups considering only four studies were used for this portion of the analyses. The details of the subgroup analyses are summarized in Table [2](#T2){ref-type="table"}.

###### Subgroup analyses for OS and DFS/RFS

                                       OS   I^2^                              DFS/RFS   I^2^                                     
  ----- ------------------------------ ---- --------------------------------- --------- ------ --------------------------------- ------
  PLR   Overall                        20   1.57 (1.41-1.75, *p*\<0.00001)    26%       14     1.58 (1.31-1.92, *p*\<0.00001 )   66%
        Geographic region                                                                                                        
        Asia                           12   1.60 (1.36-1.88, *p*\<0.00001)    40%       9      1.50(1.19-1.90, *p*=0.0007)       68%
        Non-Asia                       8    1.58 (1.39-1.80, *p*\<0.00001)    0%        5      1.71 (1.24-2.35, *p*=0.001 )      58%
        Sample size                                                                                                              
        Large (n \>200)                10   1.56 (1.31-1.86, *p*\<0.00001 )   49%       9      1.66 (1.26-2.20, *p*=0.0004)      76%
        Small (n \<200)                10   1.64 (1.44-1.87, *p*\<0.00001)    0%        5      1.38 (1.14-1.68, *p*=0.0009)      5%
        Cut-off value                                                                                                            
        ≥185\*                         12   1.66 (1.42-1.95, *p*\<0.00001)    38%       5      1.93 (1.14-3.26, *p*=0.01)        87%
        \<185                          8    1.45 (1.26-1.66, *p*\<0.00001)    0%        9      1.37 (1.19-1.56, *p*\<0.00001)    0%
        Methods to determine cut-off                                                                                             
        ROC/software analysis          8    1.53 (1.26-1.86, *p*\<0.00001 )   54%       8      1.51 (1.19-1.91, *p*=0.0007)      68%
        RPS or NR                      12   1.60 (1.41-1.81, *p*\<0.00001)    0%        6      1.80 (1.20-2.69, *p*=0.005)       65%
        Disease stage                                                                                                            
        Non-metastatic                 10   1.59 (1.32-1.91, *p*\<0.00001)    45%       11     1.71 (1.29-2.25, *p*=0.0002)      73%
        Metastatic/mixed               10   1.54 (1.36-1.75, *p*\<0.00001)    0%        3      1.34 (1.13-1.59, *p*=0.0007 )     0.06
        Variable type                                                                                                            
        Multivariable                  16   1.58 (1.37-1.81, *p*\<0.00001 )   38%       10     1.58 (1.26-1.98, *p*\<0.00001)    73%
        Univariable                    4    1.62 (1.39-1.89, *p*\<0.00001)    0%        4      1.61 (1.18-2.18, *p*=0.002)       0%
  LMR   Overall                        9    0.59 (0.50-0.68, *p*\<0.00001)    44%       4      0.82 (0.71-0.94, *p*=0.005)       29%
        Geographic region                                                                                                        
        Asia                           6    0.66 (0.58-0.76, *p*\<0.00001)    0%        3      0.83 (0.70-0.99, *p*=0.04)        52%
        Non-Asia                       3    0.52 (0.42-0.64, *p*\<0.00001)    32%       1      0.83 (0.55-1.24, *p*=0.36)        NA
        Sample size                                                                                                              
        Large (n \>200)                5    0.61 (0.50-0.75, *p*\<0.00001)    67%       2      0.78 (0.70-0.81, *p*\<0.00001)    0%
        Small (n \<200)                4    0.52 (0.40-0.68, *p*\<0.00001)    0%        2      1.01 (0.67-1.52, *p*=0.97)        46%
        Cut-off value                                                                                                            
        ≥3.00                          5    0.58 (0.48-0.71, *p*\<0.00001 )   0%        3      0.89 (0.70-1.13, *p*=0.33)        39%
        \<3.00                         4    0.61 (0.50-0.75, *p*\<0.00001)    67%       1      0.77 (0.76-0.88, *p*=0.0002)      NA
        Disease stage                                                                                                            
        Non-metastatic                 3    0.58 (0.41-0.82, *p*=0.002)       82%       2      0.78 (0.70-0.81, *p*\<0.00001)    0%
        Metastatic/mixed               6    0.60 (0.51-0.70, *p*\<0.00001)    0%        2      1.01 (0.67-1.52, *p*=0.97)        46%
        Variable type                                                                                                            
        Multivariable                  8    0.58 (0.48-0.68, *p*\<0.00001)    49%       3      0.83 (0.70-0.99, *p*=0.04)        52%
        Univariable                    1    0.64 (0.47-0.86, *p*=0.003)       NA        1      0.83 (0.55-1.24, *p*=0.36)        NA

^\*^median

Sensitivity analysis {#s2_6}
--------------------

Sensitivity analysis was performed by assessing the potential impact of individual studies on the pooled data. As illustrated in Figure [5](#F5){ref-type="fig"}, pooled HR was not significantly altered when each single study was withdrawn every time. Notably, there was substantial heterogeneity regarding the impact of LMR on DFS (I^2^=66%); however, exclusion of three studies \[[@R31], [@R37], [@R45]\] reduced the I^2^ to 0% and did not change the prognostic significance ( pooled HR =1.39, 95% CI=1.23--1.58, *p* \<0.001).

![Sensitivity analysis for meta-analysis\
**A**. correlation of PLR with OS; **B**. correlation of PLR with DFS; **C**. correlation of LMR with OS; **D**. correlation of LMR with DFS.](oncotarget-08-20011-g005){#F5}

Publication bias {#s2_7}
----------------

As shown in Figure [6](#F6){ref-type="fig"}, the funnel plots showed evidence for symmetry in studies of the impact of LMR on CRC survival, but not in studies of PLR, suggesting that a publication bias about for the effect of PLR on CRC outcomes may exist. Therefore, the Begg\'s and Egger\'s tests were conducted to assess the bias more precisely. Studies concerning PLR and pooled OS (Egger\'s test, *p*=0.048; Begg\'s test, *p*=0.127) and DFS (Egger\'s test, *p*=0.004; Begg\'s test, *p*=0.063) showed publication bias ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). After doing a trim fill analysis, we found that the pooled HR was 1.453 (95% CI = 1.286 −1.641, *p* \<0.001) for OS and 1.206 (95% CI = 0.982 −1.482, *p*=0.074) for DFS, suggesting that a publication bias appeared to overestimate DFS.

![Funnel plot for publication bias\
**A**. correlation of PLR with OS; **B**. correlation of PLR with DFS; **C**. correlation of LMR with OS; **D**. correlation of LMR with DFS.](oncotarget-08-20011-g006){#F6}

DISCUSSION {#s3}
==========

Recent studies \[[@R49]--[@R51]\] have shown correlation between the SIR and clinical outcomes in various cancers; However, conflicting evidence exists regarding the effects of PLR and LMR on the prognosis of CRC patients. In this meta-analysis of 33 studies which includes 15,404 cases, we reevaluated the prognostic roles of the PLR and LMR in CRC. The results of this study suggested that pretreatment PLR and LMR could be used as prognostic predictors in CRC patients. Elevated PLR was associated with poor OS and reduced DFS. On the contrary, high LMR was correlated with favorable OS, CSS and DFS. Analyses stratified by geographic region, sample size, different cut-off (≥185 and \<185) and methods in determining cut-off did not alter the effects of PLR and LMR on OS and DFS.

Most of included studies (82%) were published in 2014 or later, highlighting the recent interest in investigating the prognostic values of PLR and LMR in CRC. To our knowledge, the meta-analysis is a more comprehensive update that systematically and quantitatively evaluates this topic. When assessing the impact of PLR on OS, the pooled HR of three studies which defined three risk categories (binary cut-offs) did not achieve statistical significance. This may be due to numerically lower HRs that apply per higher risk category compared with using a single cutoff \[[@R52]\]. We performed a sensitivity analysis, which indicated our results were robust. Publication bias was identified by a funnel plot and the Begg\'s and Egger\'s tests. The results revealed that studies concerning PLR and pooled OS and DFS showed publication bias, indicating that results, especially those regarding the impact of PLR on DFS, should be interpreted with caution.

The underlying mechanisms by which PLR and LMR influence the survival of CRC patients remains largely unknown. Several hypotheses have been put forward to explain the underlying biological basis. Thrombocytosis is commonly observed in cancer patients and is linked with decreased survival \[[@R53]\]. Platelets can release a myriad of growth factors which may facilitate cancer growth and dissemination. Orellana *et al*. \[[@R54]\] co-cultivated ovarian cancer cells with human platelets and found that platelet-cancer interactions contributed to the formation of metastatic foci. In addition, blockade of key platelet receptors attenuated ovarian cancer metastasis. Lymphocytopenia is a key component of a high PLR. Lymphocytes represent the cellular basis of cancer immunosurveillance. Compelling evidence indicates that lymphocytes induce cytotoxic cell death and inhibit tumor cell proliferation and migration, thereby dictating the host\'s immune response to cancer \[[@R55]\]. Decreased lymphocyte counts may lead to downregulation of the immune response against cancer. Monocytes may reflect the formation of tumor-associated macrophages(TAMs), which represent pivotal components of tumor microenvironment promoting progression \[[@R56]\]. Furthermore, PLR and LMR are representative indexes of SIR. Aberrant SIR is considered to be associated with cancer progression. In addition, systemic inflammation can decrease organ function in cancer patients; thus, poor oncologic outcomes are observed \[[@R57]\].

Several potential limitations of this study should be acknowledged. First, the major disadvantage of this study was the discordance of PLR and LMR cut-offs, which lead to inter-study heterogeneity. Second, patients receiving neoadjuvant chemotherapy were included in many of the studies, which may alter the course of the survival. Third, significant heterogeneity was found in publications studying the impact of PLR on OS and DFS. In addition, several disease conditions, including liver diseases or inflammatory diseases, may affect PLR and/or LMR. Some eligible studies did not control for these confounding factors.

MATERIALS AND METHODS {#s4}
=====================

Literature search {#s4_1}
-----------------

Pubmed, Embase, and CNKI were systematically searched for literature up to June 2016. The main medical subject heading (Mesh) terms and text words included colorectal cancer, lymphocyte, platelets, monocytes and prognosis. The search strategies were summarized in [Supplementary Appendix](#SD1){ref-type="supplementary-material"}. The languages of articles were limited to English and Chinese. The bibliographies of relevant articles were also searched manually for additional eligible studies. Inter-reviewer agreement was evaluated using Cohen\'s kappa. Any disagreements were discussed and arbitrated by a second reviewer.

Study selection {#s4_2}
---------------

A study was considered eligible only if the publication met all of the following criteria: (a) patients were pathologically diagnosed with CRC; (b) pretreatment PLR and/or LMR and cutoff values were reported; (c) PLR and/or LMR were used as prognostic indicators of OS, CSS or DFS; (c) hazard ratios and 95% confidence intervals were reported in text. The exclusion criteria were as follows: (a) PLR and/or LMR were reported as continuous variables; (b) studies had overlapping or duplicated data; (c) non-research articles or studies that were based on animal or human cell lines; (d) publications were not subjected to peer-review (dissertations or theses).

Data extraction {#s4_3}
---------------

Two investigators independently gathered data. The following data were extracted: publication details (first author\'s surname, year of publication, geographic region of study), population characteristics (patients number, age, and sex), cancer and follow-up data (cancer site, stage, treatment strategy, median/mean follow-up duration, survival analysis), PLR and/or LMR data (assessment method and cut-off values), cut-off values were used to determine 'high' versus 'low' PLR and LMR.

Qualitative assessment {#s4_4}
----------------------

The quality of each of the included studies was assessed using the Newcastle--Ottawa Quality Assessment Scale (NOS, [Supplementary Table 2](#SD1){ref-type="supplementary-material"}) \[[@R58]\], which includes 3 criteria, namely, selection (0--4 points), comparability (0--2 points) and outcomes (0--3 points). NOS scores≧6 were defined as high-quality. ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}).

Statistical analysis {#s4_5}
--------------------

The HR with 95% CI was directly retrieved from each of the article. Pooled HR was calculated using the generic inverse variance and random-effect model. A combined HR \>1 implied a worse prognosis in the group with elevated PLR or LMR. Inter-study heterogeneity was measured by performing the c2-based Cochran\'s Q test and Higgins' *I^2^* statistics. A *P*-value \<0.10 and/or *I^2^*\>50% indicated significant heterogeneity. Publication bias was assessed with visual inspection of funnel plots and precisely evaluated by Egger\'s and Begg\'s tests. A *P*-value \< 0.05 in the Z test for pooled HR, or no overlap of the 95% CI with 1 was considered statistically significant. This study adhered to the PRISMA guidelines and all data analysis was performed using Review Manager 5.2 (Cochrane Collaboration, London, UK) and Stata 12.0 software (Stata Corporation, College Station, TX, USA).

CONCLUSIONS {#s5}
===========

In summary, pretreatment PLR and LMR could be used as prognostic predictors in CRC patients. Elevated PLR was associated with poor OS and DFS. In contrast, high LMR correlated with favorable OS, CSS and DFS. Further studies are necessary to confirm these findings and elucidate the underlying biology.
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